Your browser doesn't support javascript.
Clinical clustering with prognostic implications in Japanese COVID-19 patients: report from Japan COVID-19 Task Force, a nation-wide consortium to investigate COVID-19 host genetics.
Otake, Shiro; Chubachi, Shotaro; Namkoong, Ho; Nakagawara, Kensuke; Tanaka, Hiromu; Lee, Ho; Morita, Atsuho; Fukushima, Takahiro; Watase, Mayuko; Kusumoto, Tatsuya; Masaki, Katsunori; Kamata, Hirofumi; Ishii, Makoto; Hasegawa, Naoki; Harada, Norihiro; Ueda, Tetsuya; Ueda, Soichiro; Ishiguro, Takashi; Arimura, Ken; Saito, Fukuki; Yoshiyama, Takashi; Nakano, Yasushi; Mutoh, Yoshikazu; Suzuki, Yusuke; Murakami, Koji; Okada, Yukinori; Koike, Ryuji; Kitagawa, Yuko; Kimura, Akinori; Imoto, Seiya; Miyano, Satoru; Ogawa, Seishi; Kanai, Takanori; Fukunaga, Koichi.
  • Otake S; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Chubachi S; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan. bachibachi472000@live.jp.
  • Namkoong H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Nakagawara K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Tanaka H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Lee H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Morita A; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Fukushima T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Watase M; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Kusumoto T; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Masaki K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Kamata H; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Ishii M; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
  • Hasegawa N; Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
  • Harada N; Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.
  • Ueda T; Department of Respiratory Medicine, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Ueda S; JCHO (Japan Community Health Care Organization) Saitama Medical Center, Internal Medicine, Saitama, Japan.
  • Ishiguro T; Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Kumagaya, Japan.
  • Arimura K; Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.
  • Saito F; Department of Emergency and Critical Care Medicine, Kansai Medical University General Medical Center, Moriguchi, Japan.
  • Yoshiyama T; Department of Respiratory Medicine, Fukujuji Hospital, Kiyose, Japan.
  • Nakano Y; Department of Internal Medicine, Kawasaki Municipal Ida Hospital, Kawasaki, Japan.
  • Mutoh Y; Department of Infectious Diseases, Tosei General Hospital, Seto, Japan.
  • Suzuki Y; Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • Murakami K; Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Okada Y; Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
  • Koike R; Medical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo, Japan.
  • Kitagawa Y; Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
  • Kimura A; Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan.
  • Imoto S; Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Miyano S; M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
  • Ogawa S; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
  • Kanai T; Division of Gastroenterology and Hepatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Fukunaga K; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
BMC Infect Dis ; 22(1): 735, 2022 Sep 14.
Article in English | MEDLINE | ID: covidwho-2029694
ABSTRACT

BACKGROUND:

The clinical course of coronavirus disease (COVID-19) is diverse, and the usefulness of phenotyping in predicting the severity or prognosis of the disease has been demonstrated overseas. This study aimed to investigate clinically meaningful phenotypes in Japanese COVID-19 patients using cluster analysis.

METHODS:

From April 2020 to May 2021, data from inpatients aged ≥ 18 years diagnosed with COVID-19 and who agreed to participate in the study were collected. A total of 1322 Japanese patients were included. Hierarchical cluster analysis was performed using variables reported to be associated with COVID-19 severity or prognosis, namely, age, sex, obesity, smoking history, hypertension, diabetes mellitus, malignancy, chronic obstructive pulmonary disease, hyperuricemia, cardiovascular disease, chronic liver disease, and chronic kidney disease.

RESULTS:

Participants were divided into four clusters Cluster 1, young healthy (n = 266, 20.1%); Cluster 2, middle-aged (n = 245, 18.5%); Cluster 3, middle-aged obese (n = 435, 32.9%); and Cluster 4, elderly (n = 376, 28.4%). In Clusters 3 and 4, sore throat, dysosmia, and dysgeusia tended to be less frequent, while shortness of breath was more frequent. Serum lactate dehydrogenase, ferritin, KL-6, D-dimer, and C-reactive protein levels tended to be higher in Clusters 3 and 4. Although Cluster 3 had a similar age as Cluster 2, it tended to have poorer outcomes. Both Clusters 3 and 4 tended to exhibit higher rates of oxygen supplementation, intensive care unit admission, and mechanical ventilation, but the mortality rate tended to be lower in Cluster 3.

CONCLUSIONS:

We have successfully performed the first phenotyping of COVID-19 patients in Japan, which is clinically useful in predicting important outcomes, despite the simplicity of the cluster analysis method that does not use complex variables.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive / COVID-19 Type of study: Observational study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: S12879-022-07701-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pulmonary Disease, Chronic Obstructive / COVID-19 Type of study: Observational study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: S12879-022-07701-y